PP
PPCB.US Propanc Biopharma, Inc. Common Stock
- Market cap
- USD 1.88M
- P/E
- -
- P/B
- 0.20x
- ROE
- -485.9%
- Dividend yield
- 49.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is PPCB.US undervalued?
Graham numberThe Graham number of Propanc Biopharma, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Propanc Biopharma, Inc. Common Stock fundamental analysis
No fundamental analysis for Propanc Biopharma, Inc. Common Stock yet.
Propanc Biopharma, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén…
Full company profilePropanc Biopharma, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Propanc Biopharma, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -2.17K | -2.23K | -2.31K | -2.47K | -28.1K | -5.67K | -17.8K | -21.7K | - | -22.7K | -25.5K |
| Operating Income | -5.74M | -3.96M | -2.62M | -3.49M | -1.81M | -1.99M | -1.78M | -1.54M | -57.3M | -18.2M | -34.3M |
| EBITDA | -4.97M | -4.43M | -4.56M | -3.12M | -1.69M | -2.14M | -2.26M | -1.26M | -58.3M | -18.4M | -34.3M |
| Net Income | -7.87M | -7.04M | -5.76M | -4.74M | -2.03M | -2.66M | -2.66M | -1.82M | -58.9M | -18.9M | -34.4M |
| EPS | -49,168,750 | -43,993,750 | -5,758,000 | -2,370,500 | -675,333 | -886,029 | -26,606 | -1,285 | -15 | -168 | -49 |
| Balance Sheet | |||||||||||
| Total Assets | 95.1K | 71.4K | 102K | 98.5K | 13.1K | 81.7K | 60.3K | 72.4K | 19.6M | 12.8M | 10.3M |
| Total Liabilities | 5.54M | 6.82M | 4.40M | 3.74M | 3.08M | 3.11M | 3.18M | 3.85M | 5.73M | 3.38M | 3.26M |
| Shareholders' Equity | -5.44M | -6.75M | -4.30M | -3.64M | -3.07M | -3.02M | -3.12M | -3.78M | 13.9M | 9.40M | 7.07M |
| Cash & Short-term Investments | 69.0K | 19.9K | 2.39K | 67.0K | 2.26K | 4.07K | 10.0K | 21.1K | 12.1K | 832K | 258K |
| Total Debt | 3.40M | 4.55M | 1.56M | 1.50M | 680K | 1.04M | 546K | 948K | 1.73M | 48.3K | 42.7K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.15M | -2.18M | -2.06M | -1.85M | -1.15M | -1.44M | -1.11M | -935K | -405K | -5.68M | -7.88M |
| Capital Expenditure | 1.00 | 2.18M | 2.87K | 1.00 | 4.00 | 4.00 | 1.00 | 2.00 | 2.00 | 4.94K | 0.00 |
| Free Cash Flow | -2.15M | -2.18M | -2.06M | -1.85M | -1.15M | -1.44M | -1.11M | -935K | -405K | -5.68M | -7.88M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | - | -423.7% | -200.6% | -485.9% |
| ROA | -8,275.0% | -9,860.3% | -5,664.4% | -4,812.3% | -15,464.5% | -3,255.4% | -4,410.2% | -2,515.8% | -300.1% | -147.6% | -332.7% |
| Debt to Equity | - | - | - | - | - | - | - | - | 0.12x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Propanc Biopharma, Inc. Common Stock dividends
- Dividend yield
- 49.68%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 932K | 8.30 | - |
| 2025 | - | - | - |
| 2024 | USD 193K | 136 | - |
| 2023 | USD 466K | 4,663 | - |
| 2022 | USD 700K | 233,447 | - |
| 2021 | USD 392K | 130,583 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Oct 26, 2026.
Who owns Propanc Biopharma, Inc. Common Stock
- Insiders 38.12%
- Institutions 0.86%
- Public & others 61.02%
- Shares outstanding 1.05M
- Free float 291K
Top institutions holding PPCB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 25.6K | 0.26% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 12.1K | 0.12% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 10.2K | 0.10% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Sassicaia Capital Advisers LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Marex Group Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Propanc Biopharma, Inc. Common Stock company profile
- Company name
- Propanc Biopharma, Inc. Common Stock
- Ticker
- PPCB.US
- Exchange
- USA Stocks
- Listed since
- Nov 12, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- June
- Address
- 302, 6 Butler Street, Camberwell, VIC, Australia, 3124
- Phone
- 61 3 9882 0780
- Website
- propanc.com
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Propanc Biopharma, Inc. Common Stock management
2- Mr. James NathanielszCEO & Executive Chairman · born 1974
- Ms. Jeannine ZimmermanChief Financial Officer · born 1977